Related Experiment Videos
Precision medicine with MET exon 14: a partial success
1Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
The Lancet. Oncology
|October 3, 2024
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer.
Current oncology (Toronto, Ont.)·2023
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Current oncology (Toronto, Ont.)·2023
Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.
Current oncology (Toronto, Ont.)·2022
Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review.
Current oncology (Toronto, Ont.)·2022
Canadian Consensus Recommendations on the Management of MET-Altered NSCLC.
Current oncology (Toronto, Ont.)·2021
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
Lung cancer (Amsterdam, Netherlands)·2017
Precision Medicine in patients with rare forms of genetic obesity: Necessity for coordinated and structured care.
The Journal of clinical endocrinology and metabolism·2026
Exosomes in brain diseases: Mechanisms, advances, and perspectives.
Bioactive materials·2026
Quantification of Ocular Gene Therapy-Related Inflammation Using the VRMACS Grading System.
Ophthalmology science·2026